骨髓基质细胞(BMSC)和骨膜衍生细胞(PDC)代表了有希望的骨骼干细胞来源,可用于治疗临界尺寸的骨缺损。然而,具有各种体内数据的大量临床前测试使进一步临床转化的细胞选择变得复杂.本系统评价旨在分析直到2020年11月所有已发表的临床前实验中BMSCs和基于PDCs的方法的体内骨形成功效。为此,四个数据库(PubMed,Embase,Cochrane中央对照试验登记册,和WebofScience)搜索合格的文献,共产生了94篇全文供系统审查。这篇综述产生了基于证据的BMSC或基于PDC的方法列表,这些方法已在不同的动物模型中评估了骨形成。其中,包括74项研究进行成对和网络荟萃分析。结果表明,与裸露的支架相比,PDC和BMSC均具有有益的骨形成功效。此外,基于BMSC和PDC的方法在体内骨形成功效方面没有显着差异。然而,基于BMSC的方法比基于PDC的方法具有更高的概率。此外,这篇综述讨论了(I)基于细胞的方法的体内评估可能存在的偏倚风险,(ii)由于对方法和结果的频繁不良报告而难以复制此类实验,和(iii)目前使用的基于BMSC和PDC的方法的临床相关性。系统评价注册:该研究在PROSPERO进行了前瞻性注册,注册号CRD42021270922。
Bone marrow stromal cells (BMSCs) and
periosteum-derived cells (PDCs) represent promising skeletal stem cell sources to treat critical-size bone defects. However, the large number of preclinical tests with a variety of in vivo data complicates the selection of cells for further clinical translation. This systematic
review aims to analyze the in vivo bone-forming efficacy of BMSCs- and PDCs-based approaches in all published preclinical experiments until November 2020. For this purpose, four databases (PubMed, Embase, Cochrane Central Register of Controlled Trial, and Web of Science) were searched for eligible literature, which yielded a total of 94 full-text articles for systematic review. This
review generated an evidence-based list of BMSC- or PDC-based approaches, which have been evaluated for bone formation in different animal models. Among them, 74 studies were included for pairwise and network meta-analysis. The results revealed that both PDC and BMSC had beneficial bone-forming efficacy compared to bare scaffold. In addition, BMSC- and PDC-based approaches had no significant difference regarding in vivo bone-forming efficacy. However, BMSC-based approach had a higher probability to be ranked better than PDC-based approach. Furthermore, the
review discusses (i) the possible risk of bias of the in vivo evaluation of cell-based approaches, (ii) the difficulty in replication of such experiments due to frequent poor reporting of the methods and results, and (iii) the clinical relevance of the currently utilized BMSC- and PDC-based approaches. Systematic
review registration: The study was prospectively registered in PROSPERO, Registration No. CRD42021270922.